Offered through our partner laboratory, Adgyl Lifesciences
Chronic inflammation and autoimmune diseases pose major challenges in therapeutic discovery and development. Through its partner laboratory Adgyl Lifesciences, Eurofins Advinus offers a portfolio of validated in vivo disease models that enable pharmaceutical and biotech companies to make informed, data-driven decisions before clinical trials improving the predictive success of novel therapies.
Inflammatory Bowel Disease (IBD) Models
Inflammatory bowel diseases like ulcerative colitis and Crohn’s disease require accurate and reproducible models. Adgyl Lifesciences offers several well-characterized models for evaluating anti-inflammatory and immunomodulatory agents:
- DSS-Induced Ulcerative Colitis (Mice): A chemically induced model simulating colonic inflammation typical of ulcerative colitis.
- TNBS-Induced Crohn’s Disease (Rat): Represents the chronic, relapsing intestinal inflammation of Crohn’s disease.
- Oxazolone-Induced Colitis: A T-cell-driven model ideal for investigating immune mechanisms in colitis.
Skin Inflammation Models
Designed to study psoriasis, atopic dermatitis, and pruritus, our skin inflammation models provide reliable platforms for evaluating topical and systemic therapies:
- Imiquimod-Induced Psoriasis (Mice): A gold-standard model replicating human psoriatic lesions.
- IL-23-Induced Psoriasis (Mice): Used to evaluate IL-23-targeting therapies and emerging biologics.
- TPA-Induced Atopic Dermatitis (Mice): Assesses skin barrier dysfunction and associated inflammation.
- Oxazolone-Induced Contact Dermatitis (Mice – Acute & Chronic): Models allergic skin reactions at various stages.
- Chloroquine-Induced Itch (Mice): Useful for screening antipruritic compounds affecting neurogenic itch.
- Histamine-Induced Pruritus Model: Helps evaluate mechanisms and interventions for chronic itching.
Systemic Lupus Erythematosus (SLE) Models
SLE is a multi-organ autoimmune disease with complex pathology. Our murine lupus models, delivered via Adgyl Lifesciences, help evaluate therapies targeting immune dysregulation:
- MRL/lpr Mouse Model: A spontaneous lupus model with systemic and organ-specific autoimmune features.
- NZBWF1/J Mouse Model: Closely mimics lupus nephritis and systemic immune activation seen in human SLE.
Respiratory Inflammation Models
Chronic lung diseases, including ARDS, COPD, and IPF, require robust preclinical evaluation platforms. Our respiratory inflammation models support anti-inflammatory and antifibrotic drug discovery:
- LPS-Induced Acute Lung Inflammation (Rat & Mouse): Models acute lung injury and systemic inflammation.
- Bleomycin-Induced Pulmonary Fibrosis (IPF Model): Replicates fibrotic lung disease for screening antifibrotic agents.
Joint Inflammation Models
Autoimmune and inflammatory joint diseases, including rheumatoid arthritis (RA), benefit from proven in vivo models such as:
- Collagen Type-II Induced Arthritis (CIA, Mice): Widely used for autoimmune arthritis and anti-rheumatic drug evaluation.
- Adjuvant-Induced Arthritis (AIA, Rats): A standard model for inflammation-driven joint damage.
- Collagen Antibody-Induced Arthritis (CAIA, Mice): Enables rapid assessment of therapeutic interventions.
Multiple Sclerosis (MS) Models
For evaluating therapies targeting demyelination and neuroinflammation, our MS models simulate the progressive and relapsing-remitting phases of the disease:
- MOG35–55-Induced EAE (C57BL/6 Mice): A model of progressive MS driven by T-cell activation.
- PLP139–151-Induced EAE (SJL/J Mice): Represents relapsing-remitting MS, useful for longitudinal studies.
Why Choose Our In Vivo Disease Models?
- Clinically Relevant Platforms: Our models mirror human disease pathology, increasing translational success.
- Broad Coverage: From gastrointestinal and respiratory disorders to systemic autoimmune conditions.
- Flexible Study Designs: Protocols customized for your therapeutic goals and regulatory needs.
- Scientific Guidance: Expert support throughout—from model selection to data interpretation.
Frequently Asked Questions (FAQs)
How do I choose the most suitable in vivo disease model?
Our scientific team works closely with you to identify the most relevant model based on your research objectives, mechanism of action, and disease indication. Custom study designs are available to meet specific requirements.
Do these models replicate human disease accurately?
Yes. All models are clinically validated and designed to reflect key features of human pathophysiology, supporting more accurate drug efficacy and safety evaluations.
Can you tailor study protocols to my needs?
Absolutely. We offer fully customizable study protocols to align with your compound’s pharmacological profile, intended use, and regulatory endpoints.
What kind of data and deliverables will I receive?
You’ll receive a complete study report with raw and analyzed data, histopathology results, biomarker analysis, and expert interpretation to support informed decision-making.
Do you offer regulatory support?
Yes. Eurofins Advinus provides scientific and regulatory support throughout the study process to ensure alignment with international standards and accelerate your preclinical progress.
Accelerate Your Inflammation and Autoimmune Disease Models Today.
With access to validated in vivo disease models via Adgyl Lifesciences and the scientific oversight of Eurofins Advinus, you can confidently advance your drug discovery program with predictive insights and regulatory readiness.